title: Re: Oishi et al.: LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy (Ophthalmology 2014;121:1151-2).
authors.affiliation: National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore; Fundus Image Reading Center, National Healthcare Group Eye Institute, Singapore. Electronic address: Colintan_eye@yahoo.com.sg.
authors.forename: Colin S
authors.initials: CS
authors.lastname: Tan
authors.affiliation: National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.
authors.forename: Wei Kiong
authors.initials: WK
authors.lastname: Ngo
authors.affiliation: National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.
authors.forename: Louis W
authors.initials: LW
authors.lastname: Lim
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015862:Choroid Diseases / Q000188:drug therapy*; D006801:Humans; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011127:Polyps / Q000188:drug therapy*; D011166:Porphyrins / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D011166:Porphyrins